oNKo 038
Alternative Names: oNKo-038Latest Information Update: 11 Mar 2024
At a glance
- Originator oNKo-innate
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 28 Feb 2024 oNKo 038 is available for licensing as of 28 Feb 2024. https://www.onko-innate.com/partnerships
- 28 Feb 2024 Early research in Cancer in Australia (Parenteral) before February 2024 (oNKo-innate pipeline, February 2024)